(Q35009456)

5 August 2017

1 reference

title

Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors (English)

1 reference

5 August 2017

Pang H Chong

1

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Annals of Pharmacotherapy

5 August 2017

published in

1 reference

5 August 2017

volume

36

1 reference

5 August 2017

issue

12

1 reference

5 August 2017

page(s)

1907-1917

1 reference

Are drugs within a class interchangeable?

5 August 2017

cites work

1 reference

Cerivastatin and gemfibrozil-associated rhabdomyolysis

21 January 2018

1 reference

Rosuvastatin for the treatment of patients with hypercholesterolemia

21 January 2018

1 reference

Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia

21 January 2018

1 reference

Optimizing the pharmacology of statins: characteristics of rosuvastatin

21 January 2018

1 reference

Clinically relevant differences between the statins: implications for therapeutic selection

21 January 2018

1 reference

Current perspectives on statins

21 January 2018

1 reference

The evolving role of statins in the management of atherosclerosis

21 January 2018

1 reference

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

21 January 2018

1 reference

Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects

21 January 2018

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis

21 January 2018

1 reference

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

21 January 2018

1 reference

Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project

21 January 2018

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

21 January 2018

1 reference

Why some patients respond poorly to statins and how this might be remedied

21 January 2018

1 reference

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

21 January 2018

1 reference

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

21 January 2018

1 reference

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

21 January 2018

1 reference

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

Non-lipid-lowering effects of statins on atherosclerosis

21 January 2018

1 reference

Statins and inflammatory markers

21 January 2018

1 reference

Statins: effective antiatherosclerotic therapy

21 January 2018

1 reference

Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes

21 January 2018

1 reference

Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.

21 January 2018

1 reference

Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients

21 January 2018

1 reference

The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression.

21 January 2018

1 reference

Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.

21 January 2018

1 reference

Comparative study of HMG-CoA reductase inhibitors on fibrinogen

21 January 2018

1 reference

Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.

21 January 2018

1 reference

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

21 January 2018

1 reference

Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.

21 January 2018

1 reference

Levels of soluble cell adhesion molecules in patients with dyslipidemia

21 January 2018

1 reference

Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients.

21 January 2018

1 reference

Effect of pravastatin on outcomes after cardiac transplantation.

21 January 2018

1 reference

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

21 January 2018

1 reference

Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease

21 January 2018

1 reference

Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy

21 January 2018

1 reference

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

21 January 2018

1 reference

Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease

21 January 2018

1 reference

Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease

21 January 2018

1 reference

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit

21 January 2018

1 reference

Natural statins and stroke risk.

21 January 2018

1 reference

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.

21 January 2018

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

21 January 2018

1 reference

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

Withdrawal of cerivastatin from the world market

21 January 2018

1 reference

The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases

21 January 2018

1 reference

Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells

21 January 2018

1 reference

Effect of Fluvastatin on Lipids and Fibrinolysis in Coronary Artery Disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1C116

1 reference

5 August 2017

1 reference